Sutimlimab vs B-Cell-Targeted Therapy in Cold Agglutinin Disease: Which Is the Optimal Approach? - PubMed
4 hours ago
- #Autoimmune Hemolytic Anemia
- #Cold Agglutinin Disease
- #Sutimlimab
- Cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia caused by monoclonal IgM autoantibodies.
- Traditional therapy includes B-cell-targeted immunosuppression with rituximab, which yields partial responses in about half of patients.
- Combination therapies like rituximab with fludarabine or bendamustine increase response rates but carry infectious risks.
- Sutimlimab, a C1s complement inhibitor, rapidly increases hemoglobin levels, reduces hemolysis, and improves quality of life.
- Sutimlimab does not target the B-cell clone or reduce cold agglutinin levels.
- Unmet needs include identifying patients who can discontinue sutimlimab while maintaining remission and developing effective combination strategies.